Xinnate currently develops the first application with BioC as the active product ingredient. The product, a treatment gel for inflammatory skin disease is in clinical phase and we expect to have clinical proof of concept in 2024. Next step is to further exploit the BioC platform and develop a diverse portfolio of applications.

The overall strategy is to develop each drug concept to a point when a commercial deal with a larger pharmaceutical company with global presence can be realized. Such transactions may include out-licensing-partnering/licensing, strategic partnerships, joint ventures or sales of the assets.

Read more about our: